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Abstract
Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the
Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed
characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to
enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular
and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform
conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant
therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical
associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines,
14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three
morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological
and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle
subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis,
advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and
Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype
expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform
conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for
selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.
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Introduction
Epithelial ovarian cancer is the most lethal gynaecological
malignancy in the Western world and advanced disease remains
incurable for the majority of patients. Despite testing of diverse
treatment strategies and new cytotoxic agents, optimal primary
therapy and survival rates have not substantially changed since the
introduction of platinum and taxane treatment [1–3].
Recent insights have indicated that ovarian cancer is a collective
term for invasive pelvic cancers that are derived from different
tissues with distinct histological and epidemiological features. The
five major histiotypes have been shown to have specific genetic
profiles and should be treated as distinct diseases. High-grade
serous (HGS) carcinoma represents 80% of ovarian cancers and is
defined by TP53 mutation (96%), homologous recombination
DNA repair defects (,50%), CCNE1 amplification and genomic
instability [4–6]. By contrast, low-grade serous carcinomas are
TP53 wildtype and show frequently activating RAS pathway
mutations [7,8]. The remaining histiotypes are mucinous,
endometrioid and clear cell [3]. Activating RAS pathway
mutations are found in ,40% of the mucinous tumours while
endometrioid and clear cell tumours have PIK3CA (PI3Kinase
component, 12%, 31% respectively), and ARID1A mutations
(30%, 46%, respectively) [4,5,9,10].
Furthermore, large studies have identified several molecular
subtypes of HGS based on gene and microRNA expression [4,11].
These subtypes suggest associations with specific biological
processes (such as reactive stroma, mesenchymal, immunoreactive
and proliferation) and poor prognosis, for example in the C1
stromal-subtype identified by Tothill et al. [4,11]. Further
exploring the clinical characteristics of these biological different
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subtypes and identifying an optimal treatment could identify new
therapeutic strategies.
It is imperative that experimentally tractable in vitro models,
such as cell lines, accurately represent the different histological and
molecular subtypes in order to test new subtype-specific treatment
strategies. Worldwide, there are about 100 ovarian cancer cell
lines generated as described in literature [12–17] and about 70 of
these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or
Cancer Research Technology. Since 1990, an average of
approximately 100 papers/year are published that rely upon
ovarian cancer cell lines as a model. A major limitation for these
studies is the fact that for most of ovarian cell lines their origin is
poorly defined and owing to inadequate characterization it is not
known which distinct histological or molecular subtype is
represented.
We here describe an extensive and uniform characterization of
a collection of 39 ovarian cancer cell lines commonly used for in
vitro studies. We identified histological as well as morphological
subtypes which associate with clinical pathological characteristics
of ovarian carcinomas as well as prognosis. Furthermore, the
morphological subtypes associate with the molecular subtypes
identified by Tothill et al. [11]. In summary, these results can serve
as a guide to select appropriate cell lines representing different
histological and molecular subtype of ovarian cancer for in vitro
therapeutic studies.
Materials and Methods
Cell lines and culturing
Cell lines studied were CAOV3, CAOV4, ES-2, OV-90,
OVCAR3, TOV-112D, TOV-21G, UWB1.289, UWB1.289+
BRCA1 (purchased from ATCC), 59M, A2780, A2780CIS,
A2780ADR, ‘COLO720E’, COV318, COV362, COV362.4,
COV413A, COV413B, COV504, COV644, OAW28, OAW42,
OV56, OV7, OV17R, PEA1, PEA2, PEO1, PEO4, PEO14,
PEO16, PEO23, SKOV3 (purchased from the European collec-
tion of cell cultures, ECACC via Sigma), 2774, A2780, HOC7,
SKOV3, SKOV6 (courtesy of Gunter Daxenbichler, Dept. of
Obstetrics and Gynaecology, University of Innsbruck, Austria),
IGROV1 (courtesy of Dr. Irene Hamelers, Institute of Biomem-
branes, Utrecht University, The Netherlands). Table S1 summa-
rizes the original source of the cell lines. The cell lines A2780 and
SKOV3 were both obtained from an academic laboratory and
also purchased from ECACC, and are described here as ‘A2780
ECACC’ and ‘SKOV3 ECACC’. Thirty-nine of the 40 cell lines
were grown as monolayers, except for the semi-adherent cell line
‘COLO720E’ for which floating and attached cells were passaged.
Attached cells were fully disaggregated by trypsinization between
passages. The cell lines were maintained at 37uC in an incubator
with humidified air with 5% CO2.
All cell lines were initially cultured using the medium and
supplements as recommended by the suppliers. In contrast to
other studies, we cultured all cell lines under the same culture
conditions to avoid biases due to varying concentrations of
supplements within different media (e.g. growth factors) or
different percentages of serum. All cell lines were cultured in
RPMI-1640 glutamax, Gibco/Invitrogen supplemented with 10%
FCS (Lonza, source: Brazilian, Lot nr 1SB002), 100 U/ml
penicillin, 100 mg/ml streptomycin, 50 mg/ml gentamycin. All
experiments and nucleic acid isolations were performed after
culturing the cell lines for at least one month using these standard
conditions.
UWB1.289 is a BRCA1-null cell line from woman with a
germline BRCA1 2594delC mutation. UWB1.289+BRCA1 is
stable transfected with a pcDNA3 plasmid containing a BRCA1
insert and was maintained with 200 mg/ml Geneticin (G418) to
maintain selection for transfected cells. A2780ADR and
A2780CIS were challenged once a month with 100 nM Doxoru-
bicin and 1 mM Cisplatin respectively.
Short tandem repeat analysis
The PowerPlex 16 System (Promega) was used according to the
manufacturer’s protocol using an ABI PRISM 3100 to generate an
STR (Short tandem repeat) fingerprint of each cell line to
determine unique identity and/or lack of co-culture contamina-
tion. In addition, the STR profile was checked before and during
culturing of the cells to ensure that cross-contamination or
erroneous substitution did not occur.
Growth curves and drug sensitivity assay
The MTT colorimetric assay, which measures metabolic
activity of viable cells, was used to generate growth curves and
determine the chemosensitivity of the cell lines.
First, growth curves were generated in duplicate to determine
the optimal number of cells to use for the drug sensitivity assay.
This was done to avoid growth inhibition due to seeding not
enough cells or depletion of the medium after seeding too many
cells. The highest number of cells showing continuing exponential
growth after five days was selected for the drug response MTT
assays (Table S1, File S1).
Response curves were generated for Carboplatin, Cisplatin,
Oxaliplatin, Doxorubicin and 5-Fluorouracil (Intravenous solu-
tions, Pharmachemie, The Netherlands), Paclitaxel (Intravenous
solution, Ebewe Pharma, Austria), Docetaxel (dissolved in DMSO,
Sigma), and Gemcitabin (for intravenous use, dissolved in PBS,
Sun Pharmaceutical Industries Europe BV, The Netherlands).
Cell viability was assessed in quadruplicate using the MTT assay
after a five day exposure to 18 concentrations of the compound.
Phoenix WinNonLin 1.1 software (Pharsight) was used to fit a dose
response curve and to calculate the 50% growth inhibition values
(GI50) with error and 95% confidence intervals (see also File S1).
DNA and total RNA isolation
The NucleoSpin kit (Machery-Nagel) was used according to the
manufacturer’s protocol to isolate DNA from cells harvested with
trypsin and washed with PBS.
For the isolation of total RNA (including microRNAs),
exponentially growing cells were directly lysed in culture flasks
with RNA-Bee to avoid changes in expression due to harvesting or
washing. Total RNA was isolated from lysates as previously
described [18]. Three independent isolates of RNA from each line
were pooled for mRNA and microRNA expression analysis to
decrease possible bias from outlier values.
microRNA and gene expression analysis
For microRNA expression analysis, TaqMan Array Human
MicroRNA A fluidic Cards v2.0 (Applied Biosystems) containing
qRT-PCR assays to quantify 381 unique microRNAs were used
according to the manufacturer’s protocol. The expression data was
normalized using the median Ct of all measured microRNAs as
described by Vandesompele et al. [19] (see also File S1). The
normalized expression data for all 384 microRNAs is given in
Table S2.
Gene expression was measured using the GeneChip Human
Exon 1.0 ST Array (Affymetrix) according to manufacturer’s
protocol (see also File S1). The acquired expression data was pre-
processed using the Robust Multichip Analysis (RMA) algorithm
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within the Affymetrix Expression Console software that performs
background correction, normalization and probe set summariza-
tion per transcript resulting in one expression value per gene. The
gene expression data has been deposited in the Gene Expression
Omnibus (GSE53418).
SNaPshot mutation analysis
SNaPshot analysis was performed as described previously [20–
22] using an Applied Biosystems SNaPshot Multiplex Kit. The
nucleotide and corresponding amino acid changes evaluated were
for PIK3CA, BRAF, HRAS, NRAS and KRAS are listed in the
supplement methods (File S1).
Mutation and amplification analyses with SOLiD exon
sequencing
Processing of samples for sequencing on the SOLiD5500
sequencing platform (Life Technologies) was performed on a
Sciclone NGS liquid handling robot (Perkin Elmer), based on the
protocol for manual library preparation [23]. Sure-Select enrich-
ment for genes of interest was performed in a multiplexed fashion
of up to 16 samples per reaction (based on Nijman et al. [24])
using a custom designed enrichment kit.
Data were mapped to the reference genome (GRCh37/hg19)
using BWA and SNP and indel calling was done using a custom
analysis pipeline. Based on the COSMIC database [9] and the
review by Berns et al. [5], 53 genes that are often mutated or
amplified in ovarian cancer were selected for analyses (see
supplement methods in File S1 for the list of genes).
For the analysis of gene amplification, robust Z-scores were
calculated per exon as described by Iglewicz and Hoaglin [25]. A
gene is amplified with a Z-score greater than 2 and highly
amplified if greater than 3.
The SOLiD Exon sequencing has been deposited in the
European Nucleotide Archive (PRJEB5114).
Mutation analysis by Tagged-amplicon deep sequencing
(Tam-Seq)
The coding sequences of TP53, BRCA1, BRCA2, PTEN,
PIK3CA, EGFR and APC genes were amplified and sequenced
using the Tam-Seq method and the Fluidigm Access Array 48.48
(Fluidigm CA, USA) according to manufacturer’s protocol as
described previously [26]. Sequence analysis and variant verifica-
tion was performed as described previously [26,27]. The primer
sequences are available upon request. The Tam-Seq data has been
deposited in the European Nucleotide Archive (PRJEB5183).
Microsatellite instability
Microsatellite instability was determined using the MSI Analysis
System Version 1.2 (Promega) according to the manufacturer’s
protocol and as performed routinely electrophoresis using an ABI
PRISM 3100. MSI is determined on five mononucleotide repeat
markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27).
FACS analyses
The cells were harvested and stained with properly titrated
fluorochrome-conjugated monoclonal antibodies (as described
before [28]). In brief, cells were stained with antibodies against
luminal cytokeratin’s (CK) conjugated to PE (mixture of cytoker-
atin 8, 18 -clone C11- and cytokeratin 19 -clone A53-B/A2-,
Veridex LCC, Raritan, NJ), CD24-FITC (clone SN3, eBios-
ciences, San Diego, CA), CD44-PeCy7 (clone IM7, eBiosciences)
and EpCAM-FITC (clone EBA-1, BD Biosciences, San Jose). CK
staining was preceded by a fixation and permeabilization step
using FIX & PERM reagents (An Der Grub Bio Research GmbH,
Austria). Protein expression was measured on a FACSCanto flow
cytometer (BD Biosciences). The signal-to-noise ratio (s/n) was
calculated (i.e. geometric mean fluorescence intensity (MFI) of the
stained population divided by the MFI of the unstained
population) to correct for auto fluorescence.
Statistics and visualization
Statistical analyses were performed on the 33 cell lines that were
generated from unique ovarian cancer patient material. Duplicates
(SKOV3 and A2780), in vitro derivatives (A2780ADR,
A2780CIS, COV362.4 and UWB1.289+BRCA1) and the possibly
contaminated cell line ‘COLO720E’ were left out of these
analyses. Statistical analyses were done using nonparametric
methods within the STATA statistical package, release 12.0
(STATA Corp., College Station, TX). P-values were two-sided
and P,0.05 was considered statistically significant.
BRB array tools (v4.3.1) was used to select genes and
microRNAs differentially expressed between the three morpho-
logical subtypes. First, microRNAs with .80% missing values
were filtered out. Then missing values that were not flagged due to
low quality were replaced with the minimal value over all
microRNAs and samples followed by 2log normalization. Within
BRB, the 50% most variable microRNAs and mRNAs were
selected and the class comparison algorithm was used to calculate
the permutation p-value after 10.000 permutations. P,0.05 was
considered significant. Hierarchical clustering was done on
median centred mRNA and microRNA expression data using
Eisen Gene cluster 3.0. For the GSE9891 data set multiple probes
per gene were averaged which most closely resembles the
approach taken by the exon arrays (i.e. the probe set summari-
zation within the Affymetrix Expression Console software). Next,
the cell line gene expression data and the GSE9891 data
(excluding the LMP samples) were median centred separately to
correct for differences between the platforms used and subse-
quently combined before the hierarchical clustering. Identification
of biological function of the morphology related genes was
performed using IPA (v16542223, Ingenuity Systems).
Results
Figure 1 gives a summary of the experimental plan including
culturing all cell lines with the same culture conditions to avoid
biases due to varying concentrations of supplements within
different media (e.g. growth factors) or serum.
Short tandem repeat (STR) analysis
The measured number of repeats for each of the 16 STR loci as
well as reference STR profiles from public databanks and
literature are given in Table S3.
The concordance between the peaks of the reference profiles
and the profiles generated in this study was 100% for 22 cell lines,
90–99% for ten cell lines and 79–89% for four cell lines. For three
cell lines, there are no references available (Table S3).
One cell line, ‘COLO720E’, showed only 4% concordance with
the STR profiles published by Korch et al. [29]. COLO720E has
been described to be mixture of the COLO684 and COLO685
cell lines which are both derived from uterine adenocarcinoma
[30]. ‘COLO720E’ had two TP53 mutations described
(c.1118del1, c.C413T), supporting the possibility of two cell
populations. However, these two TP53 mutations were recently
reported by Anglesio et al. although their COLO720E cell line did
match the publicly available STR reference [31]. Since
Ovarian Cancer Cell Line Panel (OCCP)
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‘COLO720E’ has been recently retracted from the ECACC cell
line repository, we excluded it from further data analyses.
Origin
The available literature information on the origin of the 39 cell
lines is summarized in Figure 2 (additional data in Table S1) [32–
53]. Thirty-three cell lines were generated from unique patient
material, not including the duplicate sources (SKOV3, A2780), in
vitro derivatives (A2780ADR, A2780CIS, COV362.4,
UWB1.289+BRCA1) and the possibly contaminated cell line
‘COLO720E’. Histology was described for 30/33 cell lines and
showed a similar frequency distribution compared to ovarian
carcinomas with the majority being serous (21/33) (Figure 2).
The origin (ascites, tumour tissue or pleural effusion), time
(primary disease, recurrence, at clinical resistance) and whether
the patient had received platinum-based chemotherapy before
culture was known in 32, 21 and 25 cell lines respectively. The
tissue-originated cell lines were mostly from platinum-naive
patients (7/8, 88%) and primary disease (6/7, 86%) whereas the
ascites-originated cell lines were more often platinum-treated (9/
15, 60%) and cultured after relapse or clinical resistance (10/12,
83%).
Microsatellite instability
Microsatellite instability for all five markers studied was
observed for: 2774, both SKOV3 sources, IGROV1, TOV21G
and ‘COLO720E’ (Figure 2). A2780ADR and A2780CIS showed
instability for four of the five markers (NR-21, BAT26, NR-24,
MONO-27) and were bi-allelic for the fifth marker BAT25. In
contrast, the parental A2780 ECACC cell line (also from the
European cell culture collection ECACC) showed only microsat-
ellite instability for one marker (NR-21) and was also bi-allelic for
BAT25. The second A2780 source from an academic laboratory
showed no microsatellite instability (only a small shift for NR-21)
but was also bi-allelic for BAT25. This indicates that different
cultures of the same cell line can develop or select genetic
differences as we described previously for different A2780 cell lines
[54].
Although the numbers are very small, the four MSI cell lines
showed significantly less concordance of their STR profile to the
reference STR profile (Mann-Whitney U test, p,0.0013) and
more mutations than the 29 non-MSI cell lines (median 13 versus
2 mutations per cell line, Mann-Whitney U test p,0.001).
Morphological subtypes
Three morphological phenotypes were distinguished based on
two independent observations of morphological and growth
characteristics during culturing from low-density up to 70/80%
confluence, i.e. cell shape, cell size and growth pattern during
culturing as well as proliferation rate. Figure S1 shows represen-
tative images of six examples of each of the three morphological
subtypes to illustrate differences in cell shape, size and growth
pattern between the morphological subtypes. The ‘Epithelial’
morphological subtype was characterized by flattened epithelial-
like cells that grew in sheets of regular or irregular clusters (n = 21).
In the ‘Round’ subtype (n = 7), cell size was smaller with a round
shape and high proliferative rate. Cells grew separately or as
irregular clusters, adhered loosely to tissue culture dishes and often
grew on top of each other. Cells with the ‘Spindle’ subtype
(n = 12), were stretched and spindle shaped and grew as separate
cells or irregular clusters.
There was an association between morphology and the origin of
the 33 unique cell lines, 74% of Epithelial cell lines originated from
ascites (14/19), all four Round cell lines were culture from tissue,
while Spindle cell lines originated equally from ascites, tissue or
pleural effusion (all 3/9, 33%) (Fisher’s exact p = 0.002). Although
not significant, Epithelial cell lines were more often of serous origin
(83%) compared to Round (33%) and Spindle (56%) cell lines
(Fisher’s exact, p = 0.095).
Interestingly, the morphological subtype was significantly
associated with prior platinum-based chemotherapy (10/14
Epithelial had previously received platinum-based treatment
versus 4/4 Round and 7/7 Spindle untreated lines; Fisher’s exact
test, p,0.002).
Protein markers
The expression of CD44, CD24, EpCAM and luminal
cytokeratin’s are given in Figure 2.
The stem cell marker CD44 was expressed in 31/33 of the cell
lines and was associated with morphology (Kruskal-Wallis
p = 0.0037). Interestingly, 6/9 Spindle cell lines showed high
CD44 expression combined with absent CD24 expression which
has been suggested as a characteristic of stem cell populations. By
contrast, CD44high/CD242 expression was not observed in the
four Round cell lines and in only 6/20 Epithelial cell lines.
The epithelial markers EpCAM and luminal Cytokeratin’s were
expressed in most Epithelial cell lines (19/20 and 18/20
respectively) but only in one Round cell line (1/4). All Spindle
cell lines showed absent or very low expression of EpCAM but 5/9
did express luminal Cytokeratin’s. EpCAM and luminal Cytoker-
atin’s expression was associated with morphology (Kruskal-Wallis,
p,0.001 and p,0.024 respectively) as well as serous versus non-
serous histology (Mann-Whitney, p = 0.004 and p= 0.108 respec-
tively).
Gene mutation and amplification
The mutation status of 53 genes was determined with three
techniques: SNaPshot, SOLiD and/or Tam-Seq exon sequencing.
Discordant data between these three techniques were checked
manually using the raw sequence data. Table S4 lists all mutation
data which is summarized in Figure 2. In total, we detected 178
mutations in 45 genes in all 39 cell lines. The most frequently
mutated gene was TP53, mutated in 27/33 cell lines including 7/8
high-grade serous, 9/10 serous and unexpectedly in 3/3 low-grade
serous.
We determined the amplification of CCNE1, MYC, TPX2 and
ERBB2 by comparing the sequencing coverage for each exon to
the median overall coverage [55]. Amplification was observed for
CCNE1 (n = 5), MYC (n= 3), TPX2 (n= 3) and ERBB2 (n= 2)
(Figure 2, Figure S2A-C). When we compared genomic amplifi-
cation of each gene with mRNA expression, MYC and TPX2
were highly expressed in the majority of the cell lines including
lines that showed amplification (data not shown). The cell lines
showing ERBB2 or CCNE1 amplification showed the highest
expression of these genes. For CCNE1 this association was
significant (Mann-Whitney p,0.001, Figure S2D).
Figure 1. Overview of the presented data, results and in silico clinical translation. STR short tandem repeat, MSI microsatellite instability, PFS
progression-free survival.
doi:10.1371/journal.pone.0103988.g001
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Response to chemotherapeutics
For all drugs, the concentration causing 50% growth inhibition
(GI50 values) showed a two log range between sensitive and
resistant cell lines (Figure 3). Notably, median GI50 values (nM)
showed marked differences between drugs with the most widely
separated compounds, Docetaxel and Carboplatin, having a
10000-fold difference (Figure 3).
Germline mutations in BRCA1 and BRCA2 have been
associated with response to platinum drugs. However, there was
no clear association between response to platinum and mutation
status or expression of BRCA1 and BRCA2 in our experiments
(data not shown). Approximately 50% of the BRCA mutations
observed were not known to be clinically relevant (Table S4) and
therefore might not affect BRCA function. However, the two cell
lines with known germ-line mutations in BRCA1 (UWB1.289) and
BRCA2 (PEO1) were relatively sensitive to Cisplatin.
The response for all drugs showed a significant positive
correlation with the proliferation rate of the cell lines, i.e. the
doubling time (Table 1).
Table 1 shows the association between drug response and the
expression of the protein markers CD44, CD24, EpCAM and
Luminal cytokeratin’s. Interestingly, cell lines with a high CD44
expression were more sensitive to taxanes. By contrast, cell lines
showing high expression of luminal cytokeratin’s were relatively
resistant to the three platinum drugs tested, and Doxorubicin.
High expression of EpCAM was also correlated with relative
resistance to Cisplatin. Luminal cytokeratin and EpCAM are
strongly correlated and absent expression of both markers was
most commonly seen in Round cell lines that were in general very
sensitive to most therapeutics. If the four Round cell lines are
excluded, the only significant association observed was between
Oxaliplatin response and expression of luminal cytokeratin’s,
indicating that this small group of cell lines is mainly causing other
associations.
We next used the Spearman rank correlation to test for
correlation between the GI50 values and the expression of each
mRNA or microRNA in order to identify genes and microRNAs
associated with response to therapy. The number of mRNAs
Figure 2. Overview of the cell line characteristics. Morphology: E Epithelial, R Round, S Spindle, Histology & Putative Histology: S serous, HGS
high-grade serous, LGS low-grade serous, E endometrioid, C clear cell, Mx mixed, M mucinous. Origin: A ascites, T tumour tissue, TM tissue from
metastasis, TO ovarian tumour tissue, P pleural effusion. Time: P primary disease, R relapsed disease, CR at clinical resistance. Platinum treated: U
untreated, P platinum-based treatment, O other chemotherapy, R radiotherapy. Protein markers: bright red no expression (signal –to-noise ratio ,5),
light red low expression (signal –to-noise ratio 5–20), light green expression (signal –to-noise ratio 20–200), bright green high expression (signal –to-
noise ratio .200), grey not determined. Therapy response: green to red scale sensitive to resistant. Doubling time: green less than one day, yellow 1–
2days, orange .2days. MSI microsatellite instability. Gene mutations: dark blue identified by at least two methods, light blue identified by one
method, light red identified with one method BUT not with second method. Gene amplification: orange amplified (2–3x SD above the median), red
highly amplified (.3x SD above the median). The WNT/bCatenin pathway (WNT/bCAT) and homologous recombination repair (HRR) columns show
the number of mutated genes in these pathways.
doi:10.1371/journal.pone.0103988.g002
Figure 3. Box-plot of the concentration of drug causing 50% growth inhibition (GI50) for all 39 cell lines and eight therapeutics. The
whiskers extend to 1.5 times the height of the box (i.e. 25th percentile to median and median to 75th percentile) or, if there is no value in that range, to the
minimum or maximum values.
doi:10.1371/journal.pone.0103988.g003
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associated with response to the eight therapeutics tested ranged
from 22–310 genes (p,0.001) and 1–10 microRNAs (p,0.01).
Figure 4 shows for each mRNA and microRNA the correlation
and significance between its expression and response to Cisplatin
and Paclitaxel.
Putative histological subtypes
We designated cell lines as putative HGS or endometrioid/clear
cell cell lines based on four criteria. Criteria for the putative HGS
origin were: 1) HGS origin with TP53 mutation and no MSI, or 2)
serous origin with TP53 mutation and amplification of CCNE1,
MYC or TPX2. Criteria for putative endometrioid/clear cell
origin were: 1) endometrioid and/or clear cell origin, or 2)
ARID1A mutation.
Using these criteria, we deduced the putative histological
subtype for the 39 cell lines as 20 non-serous (Figure 2, last
column group 1&2) and 19 serous cell lines which included 14
high-grade serous and one low-grade serous line (Figure 2, last
column group 3–5).
From the non-serous cell lines, group 1 (see also Figure 2),
contains ten cell lines that were described to be non-serous and
only in COV362 and 59 M, a MYC amplification contradicts this.
Interestingly, group 2 includes 10 cell lines with an ARID1A
mutation which is strongly associated with clear cell or endome-
trioid histology.
From the serous cell lines, group 3 contains seven cell lines
described as high-grade serous (HGS) in origin and all, except
PEO16, show a TP53 mutation as expected for HGS tumours.
PEO16 does show a BRCA2 mutation and a TP53 mutation
might have been missed since it was sequenced with one
technique, although with a reasonable coverage (mean coverage
= 113). In addition, we identified seven other putative HGS cell
lines (Group 4) that were previously described as (low-grade)
serous or unknown histology that all show a TP53 mutation
combined with an amplification of CCNE1, MYC or TPX2 which
are characteristics of the HGS subtype.
The seven remaining putative serous cell lines, Group 5, were
described to be of serous origin and six show a TP53 mutation but
no additional HGS characteristics. OAW42 shows no TP53
mutation but a PIK3CA and a BRCA1 mutation and both
SKOV3 cell lines are MSI which is more often seen in the
mucinous and endometrioid subtypes [54]. The putative low-
grade serous cell line, HOC7, was described to be of LGS origin
and shows a KRAS but also a TP53 mutation which is not a LGS
characteristic.
Interestingly, the putative histological subtypes (in contrast to
the published histological tumour of origin) were significantly
associated with the morphological phenotypes. Twelve out of 13
HGS cell lines have an Epithelial morphology and one Spindle, 4/
6 serous cell lines have Epithelial and two Spindle morphology and
for the 13 Clear cell/Endometrioid/Mixed cell lines three have
Epithelial, four Round and six have a Spindle morphology
(Fisher’s exact p = 0.002).
Molecular subtypes
Four molecular subtypes were defined by unsupervised cluster-
ing of the expression of the 80% most variable genes (n = 17609)
and microRNAs (n= 177). The 80% most variable genes and
microRNAs were selected by ranking based on their variability in
expression across the 26 unique cell lines (excluding the seven
PEO/PEA cell lines that were not profiled).
The four clusters identified associated with specific cell line
characteristics (Figure S3). The putative histology HGS is enriched
in the second cluster while the endometrioid/clear cell putative
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histology is enriched in the two right clusters. Clusters 1 and 2
contained slower growing cell lines with mostly Epithelial
morphology, expression of EpCAM and luminal cytokeratin’s,
and showed more frequent gene amplifications and less MSI and
non-synonymous mutations compared to clusters 3 and 4.
Interestingly clusters 1 and 2 also contains more cell lines
originating from ovarian cancer cells from platinum-treated
patients suggesting that recurrences after platinum-based chemo-
therapy may contain more often slow cycling cells with epithelial
characteristics and relative resistance to chemotherapeutics.
Morphological subtype specific genes, microRNAs and
pathways
We selected 1141 genes and 18 microRNAs differentially
expressed between the three morphological subtypes (permutation
derived p,0.05) (Table S5). Hierarchical clustering using these
differentially expressed genes on the 26 unique ovarian cancer cell
lines resulted in two cell line clusters: a Spindle cluster and an
Epithelial cluster that contained a distinct subcluster of three
Round cell lines (Figure 5). In addition, three gene/microRNA
clusters could be identified showing high expression in Spindle, in
Round and in Epithelial cell lines (Figure 5). The top biological
functions and diseases of these three gene/microRNA clusters are
shown in Figure 5 together with the p-value and the number of
genes/microRNAs associated with this function or disease.
Two cell lines did not cluster with their morphological subtype,
SKOV3 clusters with Spindle instead of Epithelial (as is SKOV3
ECACC) and COV413A with Epithelial instead of Round.
Morphological subtypes associate with clinical
phenotype
We used the expression data for 267 malignant ovarian
carcinomas (GSE9891) [11] to determine the clinical significance
of the morphological subtypes seen in our cell lines. After
averaging of duplicate probes, the hierarchical clustering based
on the expression of the 1141 morphological specific genes showed
two tumour clusters, resembling 1) the Spindle-shaped cell lines
and 2) the Epithelial and Round cell lines (Figure 6). Patient and
clinicopathological features are given in Table 2 as well as their
association with the two morphological clusters. The ‘Spindle-like’
tumour cluster 1 showed a significant enrichment for metastasis as
arrayed and primary site, higher stage, sub-optimal debulking and
decreased progression-free survival (Table 2, Figure 6). There was
also a strong association with the six molecular subtypes identified
by Tothill et al. [11]. Cluster 1 contains all C1 (stromal) and most
C3 (LMP-like) carcinomas while (almost) all C4, C5 (mesenchy-
mal) and C6 (low-grade endometrioid) tumours are within Cluster
2. The C2 (immune) carcinomas are evenly divided over the two
morphological tumour clusters.
We also observed that the Spindle cell lines clustered with the
C1 (stromal) tumours, the Round cell lines with the C5-
mesenchymal subtype and the Epithelial cell lines with the C4
Figure 4. Volcano plot with the correlation between the GI50 values for Cisplatin (A&C) and Paclitaxel (B&D) and the expression of
each mRNA (A&B) or microRNA (C&D). X-axes spearman correlation, Y-axes -Log of the p-value.
doi:10.1371/journal.pone.0103988.g004
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subtype (Figure 6). The clustering of the cell lines with the different
tumour subtypes can be used to select relevant cell lines for tumour
subtype specific studies.
Discussion
Worldwide about 100 ovarian cancer cell lines are available and
since 1990, a total of over 2000 papers have been published using
these cell lines as models for ovarian cancer. Within this study we
provide an extensive characterization of 39 of these cell lines on
cellular and molecular level. The major strength of this study is
that the analyses were all uniformly performed and therefore
provide a rigorous comparison between the expression signatures
of the cell lines. This uniformity was achieved by culturing all cell
lines with the same medium and culture conditions, using the first
passages after stable growth on the standardized culture conditions
of the cell lines for all cellular and molecular analyses, and
performing the molecular analysis of all cell lines simultaneously
within one batch. We identified that the ‘COLO720E’ cell line did
not match the reference short-tandem repeat (STR) profile and
was excluded from further analyses.
The DNA mismatch repair system (MMR) is involved in repair
of errors in these STR that occur during DNA synthesis.
Therefore, defective MMR is associated with a large variability
in the length of these repeats which is called micro-satellite
instability (MSI). Indeed, the STR profiles of the MSI cell lines
showed a significant lower concordance with their reference STR
profiles. For instance, IGROV1 is one of the MSI cell lines that
has been suggested by Korch et al. to have a variable STR profile
with multiple peaks which may indicate cross-contamination [29].
Prof Korch kindly sent us their STR profiles generated from three
IGROV1 DNA isolates including one obtained directly from the
Figure 5. Hierarchical clustering based on the expression of the 1141 genes and 18 microRNAs differentially expressed between
the three morphological subtypes. Histology & Putative Histology: S serous, HGS high-grade serous, LGS low-grade serous, E endometrioid, C clear
cell, Mx mixed, M mucinous, Morphology: E Epithelial, R Round, S Spindle, Red colour high expression, Green colour low expression.
doi:10.1371/journal.pone.0103988.g005
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National Cancer Institute. Close examination of the peaks shows
an average concordance of 74% between the three references and
our profile (Table S3). Furthermore, the discordant peaks all show
a shift (or extra peak) of only one repeat difference suggesting this
could be due to ineffective repair of errors made during DNA
synthesis. Thus, although STR profiling is very important to
determine whether a cell line is contaminated or not, one should
be careful with drawing a conclusion when the cell line has a
defective MMR which can also cause multiple peaks in the STR
profile.
Furthermore, MSI cell lines showed significantly more muta-
tions per cell line then the non-MSI cell lines (median of 13 vs 2).
Similarly, MSI colorectal cancer was shown to have ten times
more non-synonymous mutations per tumour compared to non-
MSI colorectal cancer [56]. This suggests that most of the
mutations seen in MSI tumours as compared to non-MSI tumours
are passenger events. It is therefore imperative when searching for
driver mutations e.g. within the Cancer Genome Atlas (TCGA)
project to take into account the MSI status of the tumours.
To be able to develop and test subtype-specific treatments in the
correct model, it is imperative to know which histological subtype
each cell line represents. To identify HGS cell line models,
Domcke et al. analysed genomic data for 47 ovarian cancer cell
lines from the CCLE collection [13] for genetic similarity to high-
grade serous ovarian carcinomas from the TCGA data [4,57]. In
addition, Anglesio et al. used their predictive clinical algorithm
COSP (based on nine immunohistochemistry markers) to predict
the four major histological subtypes within their 32 cell lines [31].
We have tested similar assumptions for the 39 ovarian cancer cell
lines described here based on the published histology and grade of
the tumour of origin together with independent mutation analyses.
We identified 20 non-serous and 19 serous cell lines including 14
high-grade serous and one low-grade serous. Comparison of our
results with the two earlier studies [31,57] shows similar prediction
for HGS and some discrepancies for the non-serous cell lines.
Interestingly, all three studies implicated widely used ovarian
cancer cell lines like A2780, SKOV3 and IGROV1 as not being
representative of the major HGS subtype but most likely of the
Figure 6. Hierarchical clustering of 26 cell lines and 267 ovarian carcinomas based on the expression of the 1141 morphological
subtypes-associated genes (A) and the association with progression-free survival (B). The diseases and functions associated with gene
clusters A-D are shown together with the p-value and the number of genes associated (#). Red colour high expression, Green colour low expression.
doi:10.1371/journal.pone.0103988.g006
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endometrioid histological subtype. These data are very important
for the correct interpretation of previous in vitro experiments using
these lines and are vital for a rational experimental approach for
future studies to develop subtype specific treatment approaches.
Based on differences in morphological and growth character-
istics, we identified three in vitro morphological subtypes (i.e.
Epithelial, Round and Spindle). These three morphological
phenotypes were previously observed in multiple types of cancer
cell lines including cervical, gastric, prostate, colorectal, lung and
glioblastoma [59–70] and a panel of 54 breast cancer cell lines
[58]. The in vitro Round morphology has been associated with the
side population that shares characteristics with tumour stem cells
of cervical and gastric tumour cell lines [59,60] as well as with so-
called amoeboid migration [61–65]. Epithelial to mesenchymal
transition (EMT) is typically defined by the acquisition of a Spindle
morphology and up-regulation of mesenchymal markers such as
SNAIL, ZEB, TWIST, VIM, FN1 and CAV1 [66–70]. EMT is a
process in which cell adhesion properties are altered and epithelial
cells lose their cell polarity and gain migratory and invasive
properties to become mesenchymal cells. Indeed, the genes up-
regulated in the Spindle cell lines include 73 Extracellular matrix
(ECM) component genes as defined by Hynes et al. [71–73] (i.e.
21% compared to 4–5% in Round and Epithelial) including
several genes up-regulated during EMT (e.g. TGFBI, TGFBR2,
TWIST1, ZEB1, ZEB2, VIM, FN1, CAV1)(Table S5).
These morphological subtypes are observed in cell lines from
multiple tumour types and seem to associate with characteristics of
putative clinical importance. It is therefore important to translate
the in vitro morphological phenotype to a clinical phenotype. We
performed an in silico analysis to determine whether the three in
vitro identified morphological subtypes associate with clinical
characteristics including prognosis as well as the molecular
subtypes identified within ovarian carcinomas [11]. We normal-
ized the cell line and carcinoma data separately to correct for
differences between the two platforms used. However, we cannot
predict how this reflects the biological differences such as the
presence of stroma, fibroblasts and immune cells within tumour
tissue which is not present in cell lines. Clustering of the cell lines
together with the endometrioid and HGS carcinomas using the
morphology associated genes showed two tumour clusters, 1) the
Spindle-like tumours, and 2) the Epithelial and Round-like
tumours.
The 152 genes over-expressed in the Spindle-like cluster
(Figure 6, gene cluster A) associate with cell movement and
invasion and include 44 Extracellular matrix (ECM) associated
genes (e.g. ADAM12/19, 8 collagens, THBS1/2, LOX, TNC,
MMP2) as well as genes overexpressed during Epithelial-to-
Mesenchymal transition (EMT) (e.g. TGFBI, TGFBR2, TWIST1,
VIM, FN1).
ECM remodelling as well as EMT have been associated with
invasion and metastasis and thus a clinically more aggressive
subtype. Indeed, the Spindle-like tumour cluster showed a
significant enrichment for metastases as arrayed site, higher stage,
sub-optimal debulking, and decreased progression-free survival.
The increased expression of cell movement and invasion-
associated genes could explain the metastasis, higher stage and
worse prognosis observed.
We also found that the morphological tumour clusters were
associated with the six molecular subtypes C1-C6 identified by
Tothill et al. [11]. Cluster 1 contains all C1 (characterized by a
reactive stroma signature and worse prognosis) and most C3
(LMP-like) carcinomas. The worse prognosis for the C1 subtype
carcinomas previously observed by Tothill et al. thus explains the
worse prognosis seen for the spindle-like cluster. Cluster 2 contains
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most C4, C5 (characterized by a mesenchymal signature) and C6
(low-grade endometrioid) tumours. The C2 carcinomas, charac-
terized by an immune signature, are evenly divided over the two
morphological tumour clusters which could be due to presence of
immune cells in these tumours that are not present in cell lines.
However, we did observe a gene cluster (cluster B) associated with
immune response overexpressed in the C2 tumours as well as the
Spindle cell lines suggesting that there may also be a cell
autonomous effect, and it is not only the microenvironment that
contributes to the immune signature.
Closer examination of the clustering showed that the Spindle
cell lines have a very similar gene expression pattern as seen for the
C1 (stromal) tumours, the Round cell lines resembled the C5-
mesenchymal subtype and the Epithelial cell lines the C4 subtype
(Figure 6). This could imply that the in vitro morphological
phenotypes resemble the clinical molecular subtypes and could be
used to select relevant cell lines for tumour subtype specific studies.
Interestingly, 61/152 genes overexpressed in the Spindle-like
cluster (Figure 6, gene cluster A) overlap with the 292 genes up
regulated in the C1 subtype explaining the association we see
between the C1 subtype tumours and the Spindle cell lines.
Furthermore, we see a small overlap between our in vitro
morphology genes with the CLOVAR subtype signature of 100
genes [74] which is enriched for genes that are up in the
CLOVAR Mesenchymal subtype that are also high in the Spindle
subtype (12/19 overlapping genes). Both the C1 and the
Mesenchymal subtype show a worse prognosis [11,74] and an
increase in (reactive) stromal gene expression that for the C1
subtype correlates with extensive desmoplasia and low tumour cell
percentage. This suggests a greater contribution of the stromal
compared to the epithelial tumour cells in these subtypes. Indeed,
stromal fibroblasts play an important role in tumourigenesis and
prognosis in several cancer types [75–77]. However, with our
analyses of 39 cell lines we show that the spindle-shaped epithelial
tumour cells also strongly contribute to the stromal signature
underlining the importance of an epithelial tumour cell autono-
mous effect additive to the stromal cells.
The tumour microenvironment is also involved in multidrug
resistance through a range of putative mechanisms, e.g. by
decreasing drug concentrations through increased interstitial fluid
pressure, 3D structure or by activating cellular pathways through
ECM-Integrin binding, the so-called cell adhesion-mediated drug
resistance (CAM-DR) [78]. In earlier studies we also observed an
association between (TGFbeta-induced) ECM remodeling during
EMT and chemotherapy resistance in ovarian cancer [18,79] as
well as endocrine therapy resistance in breast cancer [80–82].
This relation between mesenchymal subtype and therapy
resistance was not observed for the Spindle cell lines. Possibly
since within cell lines the cross-talk between the mesenchymal
tumour cells and stroma is limited to the autonomously produced
ECM and could therefore not fully mimic the clinical impact of the
tumour microenvironment.
Although Spindle morphology itself was not associated with
taxane response, one of the Spindle cell line characteristics, i.e.
high CD44 expression, did associate with response to taxanes. The
microtubules targeted by taxanes are indeed very important in cell
movement which could explain why CD44-high Spindle cell lines
were more sensitive. The literature suggests that CD44 high
tumour cells display increased self-renewal, migration and therapy
resistance and are suggested to be cancer initiating cells (CIC) [83–
86]. Also in ovarian cancer, increased density of CD44 positive
cells was associated with chemotherapy resistance [87,88].
Interestingly, conjugates of Paclitaxel with the CD44 ligand
hyaluronic acid were shown to be more effective in reducing
tumour burden in implanted CD44 positive human ovarian
carcinoma mouse models compared to free Paclitaxel [89,90].
These data might suggest that by adding these conjugates to
platinum-based chemotherapy, the CD44 positive (CIC) cells
might be specifically targeted thereby decreasing CIC initiated
relapses.
In summary, our study provides a uniformly generated data
resource for a panel of 39 ovarian cancer cell lines. We identified
histological as well as morphological subtypes which were
associated with clinical pathological and molecular characteristics
of ovarian carcinomas and prognosis. Therefore, this study is of
considerable research value to those looking for better defined
model systems with consistency to valid clinical phenotypes.
Supporting Information
Figure S1 Representative images of six examples of
each of the three morphological subtypes to illustrate
differences in cell shape, size and growth pattern
between the morphological subtypes (50% confluence,
100x magnification).
(TIF)
Figure S2 CCNE1 amplification in three categories: A.
no (n=26, three examples shown), B. medium (2–3x
MAD above the median, n=2) and C. high amplification
(.3x MAD above the median, n=3). The Y-axes represents
the number of median absolute deviation (MADs) from the
median coverage (Z-score), the maximum is given above each
graph, each bar in the histogram represents an exon of the gene,
blue bars are exons with .1.5 MAD above the median. D.
CCNE1 mRNA expression (y-axes) relative to yes or no gene
amplification (x-axes) (Mann-Whitney p,.001).
(TIF)
Figure S3 Unsupervised clustering of the 26 unique
ovarian cancer cell lines using the 80% most variable
expressed mRNAs and microRNAs. Morphology: E Epithe-
lial, R Round, S Spindle,Histology & Putative Histology: S serous,
HGS high-grade serous, LGS low-grade serous, E endometrioid,
C clear cell, Mx mixed, M mucinous, Time & treatment: P
primary disease, PU untreated primary disease, RU untreated
relapsed disease, RP platinum treated relapsed disease, U
untreated, (R)O (relapsed) disease that received other treatment,
CRP at clinical resistance and platinum treated. Protein markers:
bright red no expression (signal–to-noise ratio ,5), light red low
expression (signal–to-noise ratio 5–20), light green expression
(signal–to-noise ratio 20–200), bright green high expression
(signal–to-noise ratio .200), grey not determined. Median
response: of eight therapeutics green to red scale sensitive to
resistant. Doubling time: green less than one day, yellow 1–2days,
orange .2days. MSI microsatellite instability. # mutations: total
number of mutations. Gene amplification: orange amplified (2–3x
SD above the median), red highly amplified (.3x SD above the
median). Heatmap: Red colour high expression, Green colour low
expression.
(TIF)
Table S1 Background information on the origin of the
cell lines based on literature.
(XLSX)
Table S2 Normalized expression data for 384 micro-
RNAs in all 39 cell lines.
(XLSX)
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Table S3 Short tandem repeat profiles of 39 cell lines
measured with the PowerPlex 16 system (in bold)
compared to the reference STR profiles from the cell
line banks ECACC and ATCC (in italic) and STR profiles
measured by Korch et al. (in regular font). See Korch et al.
[29] for the origin of these cell lines. nd not determined.
(XLSX)
Table S4 Overview table of all mutations detected in the
39 cell lines measured by exon sequencing (SOLID and
Tam-Seq), Sanger sequencing and SNApSHOT analysis.
(XLSX)
Table S5 Morphological subtype associated genes
(n=1141) and microRNAs (n=18). The table includes the
corresponding cluster (High in Spindle, High in Round, High in
Epithelial) as well as whether the gene is an extracellular matrix
component according to Hynes et al. [71–73].
(XLSX)
File S1 Supplemental methods.
(DOCX)
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